Updates in Current and Emerging Oral Treatment Options in Relapsing-Remitting Multiple Sclerosis

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.

Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.

Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.

Experts in neurology present long-term efficacy and safety data of oral DMTs in the treatment of MS and share their perspective on the real-world significance.

Ahmed Zayed Obeidat MD, PhD, and Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, discuss the use of oral cladribine in the treatment of MS.

Experts in neurology highlight the factors they consider when switching treatments for a patient with MS.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of the different types of Bruton tyrosine kinase inhibitors (BTKi) in management of MS.

Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.